Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Centessa Pharmaceuticals, Rivus Pharmaceuticals, Levicept, Granular Therapeutics and Kaerus.
Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss:MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ:VSAR).
Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder.
How do I contact Francesco De Rubertis?
Has Francesco De Rubertis been buying or selling shares of Centessa Pharmaceuticals?
Francesco De Rubertis has not been actively trading shares of Centessa Pharmaceuticals during the last ninety days. Most recently, on Wednesday, December 1st, Rubertis Francesco De bought 60,304 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $12.62 per share, with a total value of $761,036.48. Learn More on Francesco De Rubertis' trading history.
Who are Centessa Pharmaceuticals' active insiders?
Centessa Pharmaceuticals' insider roster includes Mario Accardi (President of the Orexin Program), Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), Arjun Goyal (Director), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?
In the last year, Centessa Pharmaceuticals insiders bought shares 2 times. They purchased a total of 462,585 shares worth more than $5,866,686.94. In the last year, insiders at the sold shares 45 times. They sold a total of 973,366 shares worth more than $16,763,018.36. The most recent insider tranaction occured on November, 12th when CTO Tia L Bush sold 40,000 shares worth more than $1,040,000.00. Insiders at Centessa Pharmaceuticals own 7.1% of the company.
Learn More about insider trades at Centessa Pharmaceuticals. Information on this page was last updated on 11/12/2025.
